Hui Yang

Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study

Meletios Α. Dimopoulos, Hang Quach, María‐Victoria Mateos et al. · The Lancet · 2020 · 422 citations

Medicine, Pharmacology, Pharmacotherapy +14

A Multicenter Phase II Study of AMG 337 in Patients with <i>MET</i>-Amplified Gastric/Gastroesophageal Junction/Esophageal Adenocarcinoma and Other <i>MET</i>-Amplified Solid Tumors

Eric Van Cutsem, Bogusława Karaszewska, Yoon‐Koo Kang et al. · Clinical Cancer Research · 2018 · 71 citations · Full text

Medicine, Oncology, Pharmacology +17

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis Results from the Randomized, Open-Label, Phase 3 Study Candor (NCT03158688)

Saad Z. Usmani, Hang Quach, María‐Victoria Mateos et al. · Blood · 2019 · 43 citations

Medicine, Pharmacology, Pharmacotherapy +17

Concomitant overexpression of EGFR and CXCR4 is associated with worse prognosis in a new molecular subtype of non-small cell lung cancer

Alya A. Al Zobair, Barrak F. Al Obeidy, Lei Yang et al. · Oncology Reports · 2013 · 31 citations · Full text

Medicine, Molecular Biology, Oncology +13

Alpha-synuclein functions as a negative regulator for expression of tyrosine hydroxylase.

Yaohua Li, Nan Gao, Yi-Wen Ye et al. · PubMed · 2011 · 23 citations

Life Sciences, Neurobiology, Neuroscience +14